Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 27481
The MTI Photoscreener(TM) consists of a single flash placed close to the center of the lens of the subject's eye to accentuate the red eye appearance of a subject for diagnostic purposes. By placing the flash close to the lens aperture, abnormal refractive errors of the eye are imaged as white crescents in the red eye reflex, a process scientifically known as photo refraction.
IPSCIO Record ID: 1514
Technology of production intraocular lenses from collagen co-polimers Nowadays, intraocular correction is one of the basic medical treatment method of vision body disease.
Artificial eye linses are used not only when cataract, but also for removal of refraction anomalies.
Artificial eye lenses, which are implantated through small sizes, are most perspective. Several requirements are produced to artificial eye lenses like elasticity, biocompatibility, low specific density and high solidity on rupture. Artificial eye lenses from collagen co-polimers corresponds to these principles.
Highest elasticity, hight solidity on rupture are the main quality of these products. It allows to make implantation as tool-making method of injection also.
Lenses, which are maked an special technology, passed experimental and hospital tests successfully and inculcated in wide surgical practice as in Eye Microsurgery Intersectoral Research and Technology Complex so in the other Russian and CIS hospitals.
US patent N 6.286.829 (Russion application N 4745668) 'Biocompatible polymer material and a process for producing same'
USA patent N 5258025 (Russian application N 4881670) 'correctional intraocular lens'
IPSCIO Record ID: 1449
The sale and assignment of Lotemax and Alrex.
Lotemax is a topical, site-specific steroid that is used to treat steroid responsive inflammatory eye conditions. The prescription eye drop is also used for post-operative eye inflammations such as experienced following cataract surgery. The novel chemical structure of Lotemax allows it to be predictably transformed by enzymes in the eye to an inactive metabolite, thereby increasing its safety profile.
Alrex is a specially developed formula of loteprednol etabonate that is used in the treatment of ophthalmic allergies. Alrex is indicated for the treatment of seasonal allergic conjunctivitis, an inflammation of the eye usually caused by pollens. Seasonal allergic conjunctivitis produces itching, tearing, redness and swelling in the conjunctiva, the membrane that covers the inside of the eyelid and the white part of the eye.
IPSCIO Record ID: 4911
Catarex removes the lens nucleus and cortex in a single step through a small incision in the eye while leaving the lens capsule functionally intact.
IPSCIO Record ID: 28481
The Company is a medical device company focused on the marketing and development of ophthalmic surgery products for use in the laser eye surgery and cataract surgery markets.